SC
DNTH icon

SMA Capital’s Dianthus Therapeutics DNTH Stock Holding History

SMA Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Buy
+110
New +$9.61K ﹤0.01% 103

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

SMA Capital's DNTH Position: Q2 2026 in Review

SMA Capital opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 110 shares worth $10.7K. The stake represents ﹤0.01% of the portfolio and ranks #103 among its holdings.

268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • SMA Capital held 110 shares of Dianthus Therapeutics worth $10.7K as of Q2 2026.
  • Dianthus Therapeutics was a new SMA Capital position in Q2 2026.
  • Dianthus Therapeutics made up ﹤0.01% of SMA Capital's portfolio in Q2 2026, its #103 holding.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.